WO2004009622A3 - Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies - Google Patents

Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies Download PDF

Info

Publication number
WO2004009622A3
WO2004009622A3 PCT/EP2003/007835 EP0307835W WO2004009622A3 WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3 EP 0307835 W EP0307835 W EP 0307835W WO 2004009622 A3 WO2004009622 A3 WO 2004009622A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
cancer
development
diseases
protein complexes
Prior art date
Application number
PCT/EP2003/007835
Other languages
English (en)
Other versions
WO2004009622A2 (fr
Inventor
Alejandro Merino
Tewis Bouwmeester
Andreas Bauer
Gerard Drewes
Martina Marzioch
Ulrich Kruse
Giulio Superti-Furga
Dirk Eberhard
Heinz Ruffner
Scott Hobson
Gerd Helftenbein
Cristina Cruciat
Original Assignee
Cellzome Ag
Alejandro Merino
Tewis Bouwmeester
Andreas Bauer
Gerard Drewes
Martina Marzioch
Ulrich Kruse
Giulio Superti-Furga
Dirk Eberhard
Heinz Ruffner
Scott Hobson
Gerd Helftenbein
Cristina Cruciat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ag, Alejandro Merino, Tewis Bouwmeester, Andreas Bauer, Gerard Drewes, Martina Marzioch, Ulrich Kruse, Giulio Superti-Furga, Dirk Eberhard, Heinz Ruffner, Scott Hobson, Gerd Helftenbein, Cristina Cruciat filed Critical Cellzome Ag
Priority to AU2003281515A priority Critical patent/AU2003281515A1/en
Publication of WO2004009622A2 publication Critical patent/WO2004009622A2/fr
Publication of WO2004009622A3 publication Critical patent/WO2004009622A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des complexes protéiniques qui entrent en jeu dans des processus cellulaires qui se sont avérés critiques pour le développement de diverses formes de cancer, des protéines composant de ces complexes, des fragments et des dérivés de ces protéines composant et, des anticorps spécifiques de ces complexes. Cette invention concerne aussi des techniques d'utilisation de ces complexes et leur protéines d'interaction dans la recherche, le diagnostic et la thérapie, entre autres domaines d'utilisation, ainsi que des techniques de préparation de ces complexes.
PCT/EP2003/007835 2002-07-19 2003-07-18 Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies WO2004009622A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003281515A AU2003281515A1 (en) 2002-07-19 2003-07-18 Protein complexes of cellular networks underlying the development of cancer and other diseases

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
EP02016111.3 2002-07-19
EP02016123.8 2002-07-19
EP02016128 2002-07-19
EP02016109 2002-07-19
EP02016128.7 2002-07-19
EP02016109.7 2002-07-19
EP02016111 2002-07-19
EP02016123 2002-07-19
EP02016427 2002-07-22
EP02016427.3 2002-07-22

Publications (2)

Publication Number Publication Date
WO2004009622A2 WO2004009622A2 (fr) 2004-01-29
WO2004009622A3 true WO2004009622A3 (fr) 2004-09-10

Family

ID=30773697

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007835 WO2004009622A2 (fr) 2002-07-19 2003-07-18 Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies

Country Status (2)

Country Link
AU (1) AU2003281515A1 (fr)
WO (1) WO2004009622A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US12121590B2 (en) 2023-06-06 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
CA2522700A1 (fr) * 2003-04-18 2004-11-04 Cytovia, Inc. Procedes pour traiter des maladies entrainant l'induction d'apoptose et essais de criblage
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
US10337054B2 (en) 2004-02-02 2019-07-02 Quantum-Si Incorporated Enrichment of nucleic acid targets
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
WO2005124360A2 (fr) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Utilisation d'une proteine tebp en tant que marqueur pour le cancer du sein
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (fr) 2004-09-23 2013-12-10 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
US20070065421A1 (en) * 2005-09-16 2007-03-22 Firestein Gary S Inducing expression of puma to reduce joint inflammation in the treatment of arthritis
EP1986675A2 (fr) * 2006-02-24 2008-11-05 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Gènes modificateurs de la matrice extracellulaire/de métastase pour la prévention ou l'inhibition de la métastase ou de la croissance tumorale et pour la caractérisation d'une tumeur
WO2008104805A2 (fr) * 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
IN2012DN03025A (fr) 2009-09-09 2015-07-31 Ct Se Llc
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
RU2626537C2 (ru) 2010-06-08 2017-07-28 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
WO2012038744A2 (fr) * 2010-09-22 2012-03-29 Genome Research Limited Détection de mutations
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
WO2012155019A1 (fr) 2011-05-12 2012-11-15 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
EP2750713B1 (fr) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués associés
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
MX364329B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
CN105102068B (zh) 2012-10-12 2018-06-01 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗体结合物
AU2013328628B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
EP2906250B1 (fr) 2012-10-12 2018-05-30 ADC Therapeutics SA Conjugués pyrrolobenzodiazepine-anticorps anti-psma
PL2906253T3 (pl) 2012-10-12 2019-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
BR112015023070B1 (pt) 2013-03-13 2022-06-07 Genentech, Inc. Conjugados e compostos de pirrolobenzodiazepinas, composição farmacêutica que compreende os mesmo, bem como seus usos para o tratamento de uma doença proliferativa
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EA201691023A1 (ru) 2013-12-16 2016-10-31 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
MX371092B (es) 2013-12-16 2020-01-16 Genentech Inc Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos.
KR20160092024A (ko) 2013-12-16 2016-08-03 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
AU2015317653A1 (en) 2014-09-17 2017-04-06 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CN107206101B (zh) 2014-12-03 2021-06-25 基因泰克公司 季铵化合物及其抗体-药物缀合物
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US11130986B2 (en) * 2015-05-20 2021-09-28 Quantum-Si Incorporated Method for isolating target nucleic acid using heteroduplex binding proteins
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
EP3299456A1 (fr) * 2016-09-26 2018-03-28 Université de Strasbourg Gène dgkk recombinant pour thérapie génique du syndrome x-fragile
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
CA3057748A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polytherapie avec un conjugue anticorps anti-axl-medicament
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
NZ761175A (en) 2017-08-18 2024-07-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
TW201920192A (zh) 2017-09-20 2019-06-01 韓商Ｐｈ製藥公司 泰蘭他汀（ｔｈａｉｌａｎｓｔａｔｉｎ）類似物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2020219504A1 (fr) * 2019-04-23 2020-10-29 The Regents Of The University Of California Modulation de la survie de cellules thérapeutiques et procédés, cellules et acides nucléiques associés à celles-ci
KR20220101108A (ko) 2019-10-29 2022-07-19 퀀텀-에스아이 인코포레이티드 유체의 연동 펌핑 및 연관 방법, 시스템, 및 디바이스
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2002092626A2 (fr) * 2001-05-15 2002-11-21 Cellzome Ag Complexe de polyadenylation et de clivage et arnm precurseur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2002092626A2 (fr) * 2001-05-15 2002-11-21 Cellzome Ag Complexe de polyadenylation et de clivage et arnm precurseur

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAUMANN PETER ET AL: "Pot1, the putative telomere end-binding protein in fission yeast and humans", SCIENCE (WASHINGTON D C), vol. 292, no. 5519, 11 May 2001 (2001-05-11), pages 1171 - 1175, XP002261020, ISSN: 0036-8075 *
BLACKBURN ELIZABETH H: "Switching and signaling at the telomere", CELL, vol. 106, no. 6, 21 September 2001 (2001-09-21), pages 661 - 673, XP002261021, ISSN: 0092-8674 *
GAVIN A-C ET AL: "Functional organization of the yeast proteome by systematic analysis of protein complexes", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, January 2002 (2002-01-01), pages 141 - 147, XP002958851, ISSN: 0028-0836 *
HO Y ET AL: "Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, 10 January 2002 (2002-01-10), pages 180 - 183, XP002250082, ISSN: 0028-0836 *
KUMAR ANUJ ET AL: "Protein complexes take the bait.", NATURE. ENGLAND 10 JAN 2002, vol. 415, no. 6868, 10 January 2002 (2002-01-10), pages 123 - 124, XP002261019, ISSN: 0028-0836 *
PAWSON^A^ ^B T ET AL: "Interaction domains: from simple binding events to complex cellular behavior", FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 513, no. 1, 20 February 2002 (2002-02-20), pages 2 - 10, XP004344928, ISSN: 0014-5793 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
US12121590B2 (en) 2023-06-06 2024-10-22 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof

Also Published As

Publication number Publication date
AU2003281515A1 (en) 2004-02-09
WO2004009622A2 (fr) 2004-01-29

Similar Documents

Publication Publication Date Title
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
WO2004013180A3 (fr) Anticorps anti-alpha-fetoproteine immu31, proteines de fusion et procedes d'utilisation de ceux-ci
WO2007067730A3 (fr) Anticorps monoclonaux humains contre la proteine tyrosine kinase 7 (ptk7) et procedes pour utiliser des anticorps anti-ptk7
WO2004029093A3 (fr) Anticorps anti-granulocytes chimeres, humains et humainises
WO2004058171A3 (fr) Anticorps anti-gpr64 et utilisations
WO2005012493A3 (fr) Anticorps anti-cd19
WO2006029219A3 (fr) Anticorps monoclonaux humains anti-ctla4 dans le traitement du cancer
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
WO2007067991A3 (fr) Anticorps monoclonaux humains se fixant a l'o8e
WO2006068975A3 (fr) Proteines de liaison specifiques de la matriptase humaine
WO2007005874A3 (fr) Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
WO2007038637A3 (fr) Anticorps monoclonaux humains diriges contre cd70
WO2005000901A3 (fr) Anticorps specifiques de cd20 et leurs methodes d'utilisation
WO2007092640A3 (fr) Anticorps qui se lient à par-2
WO2004092215A3 (fr) Methodes therapeutiques utilisant des agents liants specifiques de l'angiopoietine-2 humaine
WO2006099698A3 (fr) Nouvel anticorps anti-plgf
WO2005003298A3 (fr) Resultat de l'utilisation d'agents therapeutiques succedanes dans l'immunotherapie a base d'anti-ctla-4
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2003076592A3 (fr) Nouvelle methode d'administration et de synthese intracellulaire de molecules sirna
WO2003099205A3 (fr) Traitement du carcinome renal a l'aide d'anticorps diriges contre le recepteur du facteur de croissance epidermique
WO2001068708A3 (fr) ANTICORPS HUMAINS SPECIFIQUES DE FAP-$g(a)
WO2004094473A3 (fr) Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
EP2083018A3 (fr) Compositions et procédés associés à STOP-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP